Lindenwold Advisors INC Grows Holdings in Hologic, Inc. (NASDAQ:HOLX)

Lindenwold Advisors INC raised its position in Hologic, Inc. (NASDAQ:HOLX) by 2.0% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 30,821 shares of the medical equipment provider’s stock after purchasing an additional 595 shares during the period. Hologic accounts for approximately 1.3% of Lindenwold Advisors INC’s portfolio, making the stock its 22nd biggest holding. Lindenwold Advisors INC’s holdings in Hologic were worth $2,511,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Wolff Wiese Magana LLC acquired a new stake in shares of Hologic during the third quarter worth about $25,000. Innealta Capital LLC acquired a new stake in shares of Hologic during the second quarter worth about $25,000. iA Global Asset Management Inc. acquired a new stake in shares of Hologic during the first quarter worth $37,000. Sunbelt Securities Inc. purchased a new position in Hologic during the second quarter worth about $37,000. Finally, Cromwell Holdings LLC boosted its stake in shares of Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 416 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on HOLX shares. UBS Group lifted their price target on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Tuesday, October 15th. Royal Bank of Canada raised their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Finally, Evercore ISI increased their target price on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Trading Up 0.2 %

Shares of HOLX stock opened at $78.79 on Tuesday. Hologic, Inc. has a fifty-two week low of $67.59 and a fifty-two week high of $84.67. The firm’s 50 day moving average price is $80.63 and its two-hundred day moving average price is $78.28. The stock has a market cap of $18.30 billion, a price-to-earnings ratio of 23.66, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the previous year, the business posted $0.89 EPS. The business’s quarterly revenue was up 4.5% on a year-over-year basis. On average, analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.